Myomo, Inc.
MYO Healthcare Medical Devices
Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024. In the quarter to June 2026, revenue grew 21.3%, EPS grew 18.2%, free cash flow grew 80.0% and total debt rose 199.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow MYO
Myomo, Inc. (MYO) Piotroski F-score
Myomo, Inc.'s Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (3.00) |
| FY2024 | 5 | 0.00 |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | (2.00) |
| FY2020 | 6 | 4.00 |
| FY2019 | 2 | (3.00) |
| FY2018 | 5 | 1.00 |
| FY2017 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (38.51%) | (21.76%) | Fail | 0 |
| Positive operating cash flow | (14.51m) | (3.29m) | Fail | 0 |
| Rising return on assets | (38.51%) | (21.76%) | Fail | 0 |
| Cash flow above net income | 1.06m | 2.89m | Pass | 1 |
| Falling long-term leverage | 0.28 | 0.00 | Fail | 0 |
| Rising current ratio | 3.30 | 3.22 | Pass | 1 |
| No new shares issued | 41,856,000 | 37,759,000 | Fail | 0 |
| Rising gross margin | 65.70% | 71.23% | Fail | 0 |
| Rising asset turnover | 1.01 | 1.15 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| XTNT Xtant Medical Holdings, Inc. compare | 8 |
| SNWV Sanuwave Health Inc. compare | 6 |
| SRTS Sensus Healthcare, Inc. compare | 4 |
| TLIS Talis Biomedical Corporation compare | 4 |
| COCH Envoy Medical, Inc. compare | 3 |
| RPID Rapid Micro Biosystems, Inc. compare | 3 |
| MDAI Spectral AI, Inc. compare | 3 |
| TELA TELA Bio, Inc. compare | 3 |
| MYO Myomo, Inc. | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover